IRIS
RIZZI, Rita
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.300
AS - Asia 5.966
EU - Europa 5.554
SA - Sud America 1.681
Continente sconosciuto - Info sul continente non disponibili 386
AF - Africa 292
OC - Oceania 16
Totale 27.195
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.056
SG - Singapore 2.535
IT - Italia 2.117
CN - Cina 1.398
BR - Brasile 1.304
HK - Hong Kong 757
SE - Svezia 669
RU - Federazione Russa 528
DE - Germania 465
UA - Ucraina 448
FR - Francia 385
FI - Finlandia 383
VN - Vietnam 370
GB - Regno Unito 256
IN - India 189
BD - Bangladesh 156
AR - Argentina 131
CA - Canada 108
CI - Costa d'Avorio 97
ID - Indonesia 81
TR - Turchia 70
IQ - Iraq 65
MX - Messico 60
CO - Colombia 58
NL - Olanda 56
ZA - Sudafrica 53
EC - Ecuador 52
IE - Irlanda 47
VE - Venezuela 44
PL - Polonia 43
SA - Arabia Saudita 43
JP - Giappone 42
PK - Pakistan 42
ES - Italia 34
MA - Marocco 33
CL - Cile 28
UZ - Uzbekistan 28
JM - Giamaica 26
BE - Belgio 25
PY - Paraguay 25
TN - Tunisia 24
JO - Giordania 22
CZ - Repubblica Ceca 21
PE - Perù 21
EG - Egitto 19
PH - Filippine 18
AU - Australia 15
MY - Malesia 15
AE - Emirati Arabi Uniti 13
AT - Austria 13
ET - Etiopia 13
KE - Kenya 12
AZ - Azerbaigian 11
CR - Costa Rica 11
LT - Lituania 11
IL - Israele 10
IR - Iran 10
TH - Thailandia 10
UY - Uruguay 10
KR - Corea 9
KZ - Kazakistan 9
NP - Nepal 9
GT - Guatemala 8
HN - Honduras 8
BO - Bolivia 7
OM - Oman 7
PS - Palestinian Territory 7
HR - Croazia 6
SN - Senegal 6
TW - Taiwan 6
BY - Bielorussia 5
EU - Europa 5
LY - Libia 5
TT - Trinidad e Tobago 5
XK - ???statistics.table.value.countryCode.XK??? 5
AL - Albania 4
AO - Angola 4
CH - Svizzera 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
LB - Libano 4
MD - Moldavia 4
MN - Mongolia 4
MU - Mauritius 4
RO - Romania 4
BG - Bulgaria 3
BN - Brunei Darussalam 3
GE - Georgia 3
HU - Ungheria 3
MT - Malta 3
NI - Nicaragua 3
PT - Portogallo 3
SY - Repubblica araba siriana 3
TG - Togo 3
AM - Armenia 2
BH - Bahrain 2
BJ - Benin 2
BS - Bahamas 2
CY - Cipro 2
DK - Danimarca 2
Totale 26.772
Salva come PNG Salva come JPEG
Città #
Singapore 1.326
Ashburn 1.156
Jacksonville 1.021
Chandler 1.013
San Jose 1.000
Woodbridge 894
Fairfield 825
Hong Kong 735
Milan 702
Houston 538
Nyköping 470
Ann Arbor 455
Cambridge 431
Council Bluffs 363
Seattle 335
Beijing 329
Wilmington 298
Roxbury 256
Rome 243
Lawrence 242
Nanjing 239
Lauterbourg 238
New York 221
Boardman 188
Dallas 181
Los Angeles 179
Des Moines 161
Bari 151
Helsinki 128
Ho Chi Minh City 126
Santa Clara 109
Inglewood 107
Abidjan 96
São Paulo 96
Columbus 95
Princeton 89
Brooklyn 82
Buffalo 77
Hanoi 75
Shenyang 72
Hebei 66
Florence 61
London 61
San Diego 56
Jiaxing 52
Dearborn 51
Turin 50
Nanchang 46
Dublin 45
Figino 44
Munich 44
Chicago 43
Phoenix 43
Changsha 41
Moscow 39
Rio de Janeiro 39
Falkenstein 37
Jakarta 37
Nuremberg 37
Tianjin 37
Paris 36
Montreal 34
Tokyo 34
Frankfurt am Main 33
Guangzhou 33
Baghdad 32
Orem 32
Johannesburg 31
Warsaw 30
Toronto 29
Pune 28
San Francisco 28
Chennai 27
Naples 27
Atlanta 26
Belo Horizonte 26
Tashkent 26
Turku 26
Brasília 25
Curitiba 25
Brussels 24
Dhaka 22
Medellín 22
Redwood City 22
The Dalles 21
Washington 21
Denver 20
Istanbul 18
Jinan 18
Amsterdam 17
Manchester 17
Quito 17
Bologna 16
Campinas 16
Charlotte 16
Noicattaro 16
Salvador 16
Shanghai 16
Amman 15
Guayaquil 15
Totale 17.224
Salva come PNG Salva come JPEG
Nome #
Leucemia linfatica cronica in trasformazione prolinfocitoide: descrizione di un caso 218
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 209
LIGHT/TNFSF14 as a new biomarker of bone disease in multiple myeloma patients experiencing therapeutic regimens 203
A role of light as potential biomarker for progression of smoldering to symptomatic multiple myeloma 197
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese" 196
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 193
Non-treatment-related chronic myeloid leukemia as a second malignancy 177
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 175
Vascular Endothelial Growth Factor Serum Levels Are Elevated in Patients with Hereditary Hemorrhagic Telangiectasia 172
TRAIL effect on osteoclast formation in physiological and pathological conditions 170
CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP) 167
Amyloid in bone marrow smears of patients affected by multiple myeloma 164
ANALYSIS OF PROGNOSTIC FACTORS AND TIME TO FIRST TREATMENT IN YOUNG PATIENTS (<55 YEARS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE CENTER EXPERIENCE 160
Alteration of the osteogenic properties of bone marrow stromal cells from multiple myeloma bone disease patients 158
A case of AL amyloidosis associated with IgD multiple myeloma (MM): clinical and laboratory findings, and outcome 156
Light/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. 156
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 154
Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature 153
Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes 152
LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Non-small Cell Lung Cancer Patients 148
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 148
DARA-VD VERSUS DARA-RD AS SALVAGE THERAPY FOR PATIENTS WITH MYELOMA. INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY RETE EMATOLOGICA PUGLIESE 148
Analysis of percent identity of IGHV mutation as prognostic factor in CLL patients treated with fludarabine, cyclofosfamide and rituximab: a single centre experience 147
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients 145
A rare case of IgM-Multiple Myeloma 145
Alteration of bone remodeling in multiple myeloma bone disease: role of sclerostin 143
Autoimmune Myelofibrosis: report of three cases and review of the literature 143
The role of multiparameter flow cytometry in the work-up of IGM-monoclonal gammopathies 142
A case of light chain (AL) amyloidosis associated with IgD Multiple Myeloma (MM): clinical features, laboratory findings and outcome 141
Sclerostin is overexpressed by plasma cells from multiple myeloma patients 140
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 140
Anti-endothelial cell antibodies (AECA) in a patient wiyh Takayasu’s arteritis. In: Pathogenesis and immunotherapy of autoimmune diseases. Final program and abstract book 137
Soluble Decoy Receptor 3 (DcR3) modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients 137
Ibridizzazione in situ non isotopica. Attualità e prospettive 137
Amyloidosis: clinical picture, immunological and biomolecular features, treatment prospects 136
A weekly infusion of bortezomib reduces peripheral neuropathy 136
Hepatitis C virus infection and mixed cryoglobulinemia: a striking association 134
Altered osteogenic properties of bone marrow stromal cells from multiple myeloma patients 134
Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion 132
Another link between bone and immune system: LIGHT 132
Autoimmune hemolytic anemia during interferon-alfa therapy for chronic hepatitis C 132
CD34CD2 Acute promyelocytic leukemia (APL): is this a distinct subset? 132
Acute tubular necrosis in the hemlock poisoning 131
A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase 130
Rhabdomyolysis and acute tubular necrosis in coniine (hemlock)poisoning 129
Takayasu’s arteritis: a cell mediated large vessel vasculitis 129
The OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 129
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 129
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction 128
REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA 128
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 127
Immunogenicity of two idiotypes with a different immunoglobulin-chain distribution expressed on the same anti-CD4 Mab 127
A prospective randomized study comparing rituximab and dexamethasone vs dexamethasone alone in ITP: results of final analysis and long term follow up 125
Livelli sierici di VEGF in pazienti affetti da Sindrome di Rendu-Osler-Weber 125
Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients 125
DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION 124
Alterazione delle capacità osteogeniche in cellule stromali ottenute da midollo osseo di pazienti affetti da mieloma multiplo 121
Anti-endothelial cell autoantibodies in patients with Behcet’s disease 121
A phase II study of chlorambucil + rituximab (CLB-R) followed by R maintenance vs observation in elderly patients with previously untreated chronic lymphocytic leukemia (CLL): induction phase results 121
A phase II Study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the first interim analysis 121
Myeloma cells suppress osteoblasts through sclerostin secretion 121
T cells support osteoclastogenesis in an in vitro model derived from psoritic arthritis 120
T cells support the in vitro formation of osteoclasts in multiple myeloma-bone disease: the role of OPG/TRAIL interaction 120
Infection complications in patients with multiple myeloma treated with new drug combinations including thalidomide 120
LIGHT INVOLVEMENT IN MULTIPLE MYELOMA-OSTEOLYTIC BONE DISEASE 120
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience 118
Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function 118
In vitro osteoclastogenesis and T-cell RANKL expression in multiple myeloma-bone disease at diagnosis and in the setting of frontline treatment 117
The Role of LIGHT in Multiple Myeloma-Bone Disease 117
Malignant lymphoma involving a Warthin’s tumor: a case with immunophenotypic and gene rearrangement analysis 116
The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 116
A Phase III study of enoxaparin versus aspirin versus low-dose warfarin as thrombophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide based-regimens 115
T cells support the osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease 114
P-ANCA atipici nelle malattie infiammatorie croniche intestinali 114
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience 114
LIGHT: another link between bone and immune system 113
Irisin prevents trabecular bone damage and tumor invasion in a mouse model of multiple myeloma 113
Clinical spectrum of accidental hemlock poisoning: neurotoxic manifestations, rhabdomyolysis and acute tubular necrosis 112
What Is New in the Treatment of Smoldering Multiple Myeloma? 112
Human anti-mouse antibodies interfere in the determination of sCD4 in intravenous immunoglobulin preparations 111
Bone marrow angiogenesis in autoimmune myelofibrosis 111
Angiogenesis and hereditary hemorrhagic telangiectasia. Rendu-Osler-Weber disease 111
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 110
DCR3 involvement in multiple myeloma bone disease 110
L'AMILOIDOSI: QUADRI CLINICI, CARATTERISTICHE IMMUNOLOGICHE E BIOMOLECOLARI, PROSPETTIVE TERAPEUTICHE 110
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial 110
Failure of an in vitro model of osteoclastogenesis in human plasma cell leukaemia (PCL) 109
Chirurgia degli aneurismi dei tronchi sovraaortici 108
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia 106
Thalidomide, dexamethasone, doxil and velcade (ThaDD-V) induction therapy followed by consolidation-maintenance is very effective in early relapsed/refractory MM 105
Schnitzler's syndrome: diagnosis, treatment, and follow-up. 105
Circulating levels of cathepsin-k in multiple myeloma patients 105
Anti-endothelial cell autoantibodies in Takayasu’s arteritis 104
Autoimmune bone marrow fibrosis: a distinct clinicopathological entity 104
Kidney damage by ingestion of ethylene glicol 104
Aneurysms of the supra-aortic trunks in Takayasu's disease - Report of two cases 104
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP) 104
The role of the Wnt-signaling antagonist Sclerostin in the development of osteolytic lesions in multiple myeloma 103
[Treatment of supra-aortic trunk aneurysms: report on 16 cases]. FT Il trattamento degli aneurismi dei tronchi sovraaortici: esperienza su 16 casi. 103
[The emergency treatment of aneurysms of the supra-aortic trunks and of the internal carotid]. FT Il trattamento in urgenza degli aneurismi dei tronchi sovraortici e della carotide interna. 103
Totale 13.259
Salva come PNG Salva come JPEG
Categoria #
all - tutte 113.277
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.277
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.459 0 0 7 128 56 77 73 96 126 79 314 503
2022/20232.648 380 231 111 271 344 375 41 300 495 16 45 39
2023/20241.332 200 212 73 66 97 238 65 69 8 55 101 148
2024/20254.078 114 55 403 140 110 366 310 344 182 187 622 1.245
2025/20268.944 1.181 365 575 970 859 524 1.094 258 873 837 261 1.147
2026/20271.418 334 533 551 0 0 0 0 0 0 0 0 0
Totale 27.195